Revolution Medicines Inc.
06/07/2022 | Press release | Archived content
The Bi-steric mTORC1-Selective Inhibitor RMC-5552 in Tumors with Activation of mTOR Signaling: Preclinical Activity in Combination with RAS(ON) Inhibitors in RAS-Addicted[...]
Burris H, Ulahannan SV, Haura E, Ou SI, Capasso A, Munster P, Kitai H, Wang Z, Ling Y, Hayes J, Tao L, Wong S, Yang YC, Jiang J, Meyerowitz J, Bitman B, Singh M, Gustafson WC, Rosen N, Schram AM
ASCO Annual Meeting 2022, June 3-7, 2022, Chicago IL & Online